Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H6SH
|
|||
| Former ID |
DNCL003787
|
|||
| Drug Name |
MT203
|
|||
| Synonyms |
Namilumab
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 2 | [1], [2] | |
| Company |
National Institute of Allergy and Infectious Diseases (NIAID)
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02393378) Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02129777) Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis | |||
| REF 3 | GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.